PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 02/01/24

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...

2024-01-28 08:11:06 ET Summary Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its...

2024-01-25 13:06:47 ET More on Prime Medicine Stifel cuts Prime Medicine to hold, cites quieter catalyst outlook Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicin...

CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the...

2024-01-16 15:41:17 ET More on Prime Medicine Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Gene editing stocks gain after Eli Lilly deal amid FDA AdCom Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicine ...

2024-01-10 19:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-05 17:10:32 ET More on Prime Medicine Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Gene editing stocks gain after Eli Lilly deal amid FDA AdCom For further details see: Prime Medicine and Myeloid Therapeutics resolve all pending disputes

2024-01-05 08:29:06 ET More on Prime Medicine Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Gene editing stocks gain after Eli Lilly deal amid FDA AdCom Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicine ...

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial...

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...